Related references
Note: Only part of the references are listed.Nuclear Receptors in Cancer Inflammation and Immunity
Linjie Zhao et al.
TRENDS IN IMMUNOLOGY (2020)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
PPARγ in Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix
Rebecca L. Frkic et al.
ISCIENCE (2018)
PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue
Sun-Sil Choi et al.
DIABETES (2016)
Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency
Yu Zhang et al.
SCIENTIFIC REPORTS (2016)
Metabolic syndrome and risk of cancer: Which link?
Fernando Miguel Mendonca et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2015)
Identification of Bexarotene as a PPARγ Antagonist with HDX
David P. Marciano et al.
PPAR RESEARCH (2015)
Design, Synthesis, and Biological Evaluation of Indole Biphenylcarboxylic Acids as PPARγ Antagonists
Alice Asteian et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
sc-PDB: a 3D-database of ligandable binding sites-10 years on
Jeremy Desaphy et al.
NUCLEIC ACIDS RESEARCH (2015)
PPARG in Human Adipogenesis: Differential Contribution of Canonical Transcripts and Dominant Negative Isoforms
M. Aprile et al.
PPAR RESEARCH (2014)
Protopanaxatriol, a novel PPARγ antagonist from Panax ginseng, alleviates steatosis in mice
Yu Zhang et al.
SCIENTIFIC REPORTS (2014)
PPARγ maintains ERBB2-positive breast cancer stem cells
X. Wang et al.
ONCOGENE (2013)
Discovery of novel glitazones incorporated with phenylalanine and tyrosine: Synthesis, antidiabetic activity and structure-activity relationships
B. R. Prashantha Kumar et al.
BIOORGANIC CHEMISTRY (2012)
Targeting Peroxisome Proliferator-Activated Receptors (PPARs): Development of Modulators
Celine Pirat et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
The natural carotenoid astaxanthin, a PPAR-α agonist and PPAR-γ antagonist, reduces hepatic lipid accumulation by rewiring the transcriptome in lipid-loaded hepatocytes
Yaoyao Jia et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2012)
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Jeffrey M. Peters et al.
NATURE REVIEWS CANCER (2012)
Development, evaluation and application of 3D QSAR Pharmacophore model in the discovery of potential human renin inhibitors
Shalini John et al.
BMC BIOINFORMATICS (2011)
Structural Insight Into the Crucial Role of Ligand Chirality in the Activation of PPARs by Crystallographic Methods
F. Loiodice et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2011)
HL005-A new selective PPARγ antagonist specifically inhibits the proliferation of MCF-7
Weiqiang Lu et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2011)
Pharmacophore modeling and applications in drug discovery: challenges and recent advances
Sheng-Yong Yang
DRUG DISCOVERY TODAY (2010)
Oregano: A Source for Peroxisome Proliferator-Activated Receptor γ Antagonists
Monika Mueller et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2008)
Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types
Jack D. Burton et al.
PPAR RESEARCH (2008)
To Live or to Die: Prosurvival Activity of PPAR gamma in Cancers
Y. Lynn Wang et al.
PPAR RESEARCH (2008)
PPARs and molecular mechanisms of transrepression
Mercedes Ricote et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2007)
From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions
JN Feige et al.
PROGRESS IN LIPID RESEARCH (2006)
Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells
KL Schaefer et al.
CANCER RESEARCH (2005)
Pharmacophore modeling and three dimensional database searching for drug design using catalyst:: Recent advances
O Güner et al.
CURRENT MEDICINAL CHEMISTRY (2004)
Detailed analysis of grid-based molecular docking: A case study of CDOCKER - A CHARMm-based MD docking algorithm
GS Wu et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2003)
Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling
DJA Adamson et al.
MOLECULAR PHARMACOLOGY (2002)
Pharmacophore modeling and three-dimensional database searching for drug design using catalyst
Y Kurogi et al.
CURRENT MEDICINAL CHEMISTRY (2001)
Share Paper
